Skinvisible, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKVI research report →
Companywww.skinvisible.com
Skinvisible, Inc. , together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets.
- CEO
- Terry H. Howlett
- IPO
- 1999
- Employees
- 2
- HQ
- Las Vegas, NV, US
Price Chart
Valuation
- Market Cap
- $924.60K
- P/E
- -0.88
- P/S
- 46.23
- P/B
- -0.09
- EV/EBITDA
- -14.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -26.23%
- Op Margin
- -2412.01%
- Net Margin
- -5251.06%
- ROE
- 0.00%
- ROIC
- 10.04%
Growth & Income
- Revenue
- $20.00K · 0.00%
- Net Income
- $-1,064,034 · -88.11%
- EPS
- $-0.20 · -81.82%
- Op Income
- $-496,315
- FCF YoY
- -48588171.01%
Performance & Tape
- 52W High
- $0.90
- 52W Low
- $0.08
- 50D MA
- $0.26
- 200D MA
- $0.32
- Beta
- 1.84
- Avg Volume
- 528
Get TickerSpark's AI analysis on SKVI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 31, 23 | MCMORRAN DOREEN | other | 12,562,975 |
| Jan 31, 23 | MCMORRAN DOREEN | other | 25,125,950 |
| Jan 31, 23 | HOWLETT TERRY | other | 14,299,035 |
| Jan 31, 23 | HOWLETT TERRY | other | 28,598,070 |
| Jun 30, 19 | MCMORRAN DOREEN | other | 5,144,755 |
| Jun 30, 19 | MCMORRAN DOREEN | other | 10,289,510 |
| Jun 30, 19 | HOWLETT TERRY | other | 5,443,268 |
| Jun 30, 19 | HOWLETT TERRY | other | 10,886,535 |
| Mar 28, 18 | MCMORRAN DOREEN | sell | 1 |
| Dec 31, 18 | MCMORRAN DOREEN | other | 1 |
Our SKVI Coverage
We haven't published any research on SKVI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SKVI Report →